BXP.L Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 19:25):

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients in Bangladesh...

Stats
Šios dienos apimtis	105 000
Vidutinė apimtis	44 222.00
Rinkos kapitalizacija	162.83M
EPS	£2.13 ( 2023-03-31 )
Last Dividend	£3.32 ( 2022-11-17 )
Next Dividend	£0 ( N/A )
P/E	4.56
ATR14	£0 (0.00%)

Beximco Pharmaceuticals Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
POLX.L	0.931
FRP.L	0.923
FWD.L	0.921
KCT.L	0.92
SENS.L	0.917
GRIO.L	0.917
RESI.L	0.915
WNWD.L	0.914
GSF.L	0.913
WATR.L	0.912

10 Labiausiai neigiamai susiję koreliacijos
RR.L	-0.933
REL.L	-0.932
RSVL.L	-0.928
IL0A.L	-0.922
JDW.L	-0.917
FEDF.L	-0.911
XFFE.L	-0.91
MPO.L	-0.91
JREC.L	-0.909
EMRJ.L	-0.906

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Beximco Pharmaceuticals Finansinės ataskaitos

Annual	2022
Pajamos:	£39.27B
Bruto pelnas:	£17.31B (44.09 %)
EPS:	£10.34

FY	2022
Pajamos:	£39.27B
Bruto pelnas:	£17.31B (44.09 %)
EPS:	£10.34

FY	2022
Pajamos:	£34.67B
Bruto pelnas:	£15.81B (45.61 %)
EPS:	£11.48

FY	2021
Pajamos:	£29.49B
Bruto pelnas:	£13.92B (47.21 %)
EPS:	£11.49

Financial Reports:

No articles found.

Beximco Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
£0 (N/A)	£3.32 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)

Beximco Pharmaceuticals Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.21 - Stable (24.15%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	£0.174	2008-06-30
Last Dividend	£3.32	2022-11-17
Next Dividend	£0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	11	--
Total Paid Out	£16.75	--
Avg. Dividend % Per Year	1.38%	--
Score	3.47	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.21
Div. Directional Score	8.69	--

Next Divdend (Est)
(2024-05-24)

£0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

3.47

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield
2008	£0.174	1.17%
2009	£0.405	6.62%
2010	£0	0.00%
2011	£0	0.00%
2012	£0	0.00%
2013	£0	0.00%
2014	£0	0.00%
2015	£1.057	7.02%
2016	£1.730	7.40%
2017	£1.373	2.80%
2018	£1.354	2.48%
2019	£1.605	3.92%
2020	£1.766	4.37%
2021	£3.97	4.14%
2022	£3.32	2.69%
2023	£0	0.00%
2024	£0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for LSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SFE.L	No Dividend Player	2023-05-04	Annually	11	0.26%
ICP.L	Dividend King	2023-06-15	Semi-Annually	31	2.60%
BLND.L	Dividend Knight	2023-06-22	Semi-Annually	32	2.45%
WYN.L	Dividend Knight	2023-09-28	Semi-Annually	20	1.95%
NVT.L	Dividend Knight	2023-07-20	Semi-Annually	29	4.15%
EMR.L	Dividend Junior	2023-05-25	Annually	20	1.50%
SQZ.L	Dividend Knight	2023-10-26	Annually	5	3.33%
JEL.L	Dividend King	2023-06-01	Semi-Annually	28	2.22%
BWY.L	Dividend Knight	2023-05-25	Annually	33	2.07%
PNS.L	Dividend King	2023-06-29	Semi-Annually	31	3.82%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.118	1.500	7.64	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0696	1.200	7.68	9.22	[0 - 0.3]
returnOnEquityTTM	0.111	1.500	9.87	10.00	[0.1 - 1]
payoutRatioTTM	0.319	-1.000	6.81	-6.81	[0 - 1]
currentRatioTTM	1.628	0.800	6.86	5.49	[1 - 3]
quickRatioTTM	0.372	0.800	-2.52	-2.02	[0.8 - 2.5]
cashRatioTTM	0.0806	1.500	-0.663	-0.995	[0.2 - 2]
debtRatioTTM	0.108	-1.500	8.21	-10.00	[0 - 0.6]
interestCoverageTTM	8.27	1.000	8.05	8.05	[3 - 30]
operatingCashFlowPerShareTTM	16.12	2.00	4.63	9.25	[0 - 30]
freeCashFlowPerShareTTM	10.93	2.00	4.54	9.07	[0 - 20]
debtEquityRatioTTM	0.169	-1.500	9.33	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.437	1.000	6.04	6.04	[0.2 - 0.8]
operatingProfitMarginTTM	0.182	1.000	8.36	8.36	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.946	1.000	5.86	5.86	[0.2 - 2]
assetTurnoverTTM	0.590	0.800	9.40	7.52	[0.5 - 2]
Total Score				11.17

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	4.56	1.000	9.64	0	[1 - 100]
returnOnEquityTTM	0.111	2.50	9.92	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	10.93	2.00	6.36	9.07	[0 - 30]
dividendYielPercentageTTM	0.0632	1.500	8.42	0	[0 - 0.4]
operatingCashFlowPerShareTTM	16.12	2.00	4.63	9.25	[0 - 30]
payoutRatioTTM	0.319	1.500	6.81	-6.81	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.173	1.000	8.18	0	[0.1 - 0.5]
Total Score				6.21

Beximco Pharmaceuticals

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients in Bangladesh. The company offers allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It provides its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.